Glenmede Trust Co. NA Raises Position in Boston Scientific Corporation $BSX

Glenmede Trust Co. NA boosted its position in shares of Boston Scientific Corporation (NYSE:BSX) by 12.6% in the 1st quarter, Holdings Channel.com reports. The institutional investor owned 121,568 shares of the medical equipment provider’s stock after buying an additional 13,572 shares during the period. Glenmede Trust Co. NA’s holdings in Boston Scientific were worth $7,628,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. FWL Investment Management LLC acquired a new stake in shares of Boston Scientific in the second quarter worth approximately $26,000. Swiss RE Ltd. acquired a new position in Boston Scientific in the 4th quarter valued at $26,000. Garton & Associates Financial Advisors LLC purchased a new position in Boston Scientific in the 4th quarter valued at $26,000. Sfam LLC purchased a new position in Boston Scientific in the 4th quarter valued at $29,000. Finally, Eagle Bay Advisors LLC acquired a new stake in Boston Scientific during the 4th quarter worth $30,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Trading Up 3.7%

Shares of Boston Scientific stock opened at $48.45 on Tuesday. The stock has a 50 day moving average of $45.95 and a 200 day moving average of $61.70. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. The firm has a market capitalization of $72.02 billion, a price-to-earnings ratio of 19.62, a PEG ratio of 1.02 and a beta of 0.56. Boston Scientific Corporation has a fifty-two week low of $42.20 and a fifty-two week high of $109.50.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating the consensus estimate of $0.83 by $0.03. The business had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. Boston Scientific had a return on equity of 19.36% and a net margin of 17.50%.The company’s quarterly revenue was up 7.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, research analysts predict that Boston Scientific Corporation will post 3.3 earnings per share for the current year.

Boston Scientific declared that its board has approved a share repurchase program on Monday, May 18th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s leadership believes its shares are undervalued.

Insider Activity at Boston Scientific

In related news, Director Edward J. Ludwig bought 5,000 shares of the stock in a transaction on Friday, July 31st. The stock was bought at an average price of $45.48 per share, with a total value of $227,400.00. Following the completion of the purchase, the director directly owned 30,359 shares in the company, valued at $1,380,727.32. This represents a 19.72% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director David C. Habiger purchased 2,250 shares of the company’s stock in a transaction on Wednesday, May 20th. The shares were bought at an average price of $55.92 per share, with a total value of $125,820.00. Following the completion of the transaction, the director owned 13,878 shares of the company’s stock, valued at approximately $776,057.76. The trade was a 19.35% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders have purchased 14,800 shares of company stock worth $781,412. Company insiders own 0.34% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Oppenheimer dropped their target price on shares of Boston Scientific from $90.00 to $85.00 and set an “outperform” rating for the company in a report on Monday, July 27th. Weiss Ratings downgraded shares of Boston Scientific from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, July 7th. Bank of America lowered their price target on shares of Boston Scientific from $105.00 to $68.00 and set a “buy” rating on the stock in a research report on Monday, May 18th. Barclays dropped their price objective on shares of Boston Scientific from $96.00 to $89.00 and set an “overweight” rating for the company in a research note on Thursday, May 28th. Finally, Piper Sandler reissued an “overweight” rating and issued a $65.00 target price on shares of Boston Scientific in a research note on Friday, June 12th. Twenty-four analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $71.62.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.